SKR showcases its Q2/68 results with net profit soaring by 27% to surpass 207 million Baht, achieving total revenue of 1,544 million Baht
SKR showcases its Q2/68 performance with a net profit soaring 27% to over 207 million Baht, generating total revenue of 1,544 million Baht, an increase of 4.3% compared to the same period last year. Recently, the Board of Director approved an interim dividend of 0.09 Baht per share, with the XD date set for 28 August 2025 and payment scheduled for 11 September 2025.
Mr. Suriyan Kojonroj, Deputy Managing Director and Chief Operating Officer of Sikarin Public Company Limited, announced the results of operations for the second quarter of 2025, stating that the Company had a net profit of 207.65 million Baht, an increase of 27% compared to the same period last year. Total revenue increased by 4.3% to reach 1,544 million Baht, driven by the growth of complex disease treatments through surgeries at 7 leading medical institutes of Sikarin Bangkok Hospital. Meanwhile, Sikarin, Samut Prakan Hospital experienced significant revenue growth after launching 5 specialized medical centers to support the expansion of the industrial and residential sectors. Additionally, revenue from proactive services such as mobile health checkups through SIKARIN Connect continues to grow well, including revenues from the social security sector which grew by 12.52%.
"The results of this quarter reflect that SKR's strategy, focusing on quality growth, is on the right track. The success of concentrating on treating complex diseases through surgery and excellent cost management efficiency is evident in the strong financial figures across all dimensions, including the Company's profitability and cash flow. This success comes from the commitment of the SKR team to deliver excellent service through the concept of 'protecting with sincerity'," Mr. Suriyan stated.
Mr. Suriyan said that the success in operations is also supported by strong financial indicators, with the gross profit margin increasing to 31.78% and the EBITDA margin expanding to 27.31%. This is a result of effective management of drug, medical supply, and personnel costs, leading to costs growing at a lower rate than revenue. Meanwhile, the financial position remains highly stable, with total liabilities decreasing by 7.61%, a current ratio of 3.24 times, and a debt-to-equity ratio of only 0.22 times, indicating low financial risk and high potential for future investment.
At the same time, the quality of the brand has also been recognized internationally, having recently ranked among the Top 30 best hospitals in Thailand for the year 2025 by Newsweek magazine, along with recognition in governance by receiving a 100% score on the AGM Checklist and being listed in the ESG100 for the fifth consecutive year.
For the outlook in the second half of 2025, the Company will continue to closely monitor the economic conditions both domestically and internationally, emphasizing organic growth based on a strong and stable foundation in all dimensions. This is underpinned by ongoing investments to develop the brand to maintain excellence in medical service delivery, supporting the quality of life of Thai people and creating sustainable returns for investors.
In this regard, the Company's board of directors has resolved to approve an interim cash dividend payment of 185.20 million Baht at a rate of 0.09 Baht per share, with the XD mark set for 28 August 2025, and the interim dividend payment scheduled for 11 September 2025.
Source: กรุงเทพธุรกิจ
